LoQus23 Therapeutics announces £35 million (c.$43 million) Series A financing to advance its small molecule somatic expansion inhibition therapy for Huntington’s disease
- Financing led by leading life sciences venture capital firm Forbion, with participation from existing investors SV Health Investors’ Dementia Discovery Fund (DDF) and Novartis Venture Fund (NVF)
- Lead programme targeting MutSβ set to enter the clinic in 2026, offering a potentially disease-modifying therapy for Huntington’s disease
- Forbion General Partner Rogier Rooswinkel joins Board of Directors
Cambridge, UK, 2 October 2024 – LoQus23 Therapeutics Ltd (“LoQus23”), a private biotechnology company investigating small molecule drugs that could stop DNA instability and slow neurodegeneration in Huntington’s Disease, myotonic dystrophy type 1 and similar triplet repeat expansion diseases, today announces the successful close of its £35 million (c.$43 million) Series A financing.
